Sagimet Highlights Positive MASH Combo Data and Pipeline Progress

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialSagimet Biosciences, Inc. Class A ( (SGMT) ) just unveiled an update. On 18 December 2025, Sagimet Biosciences updated its investor presentation and issued a press release reporting positive results from a Phase 1 pharmacokinetic trial evaluating a combination of its FASN inhibitor denifanstat with the thyroid hormone receptor beta agonist resmetirom, a pairing supported by preclinical evidence of synergistic effects in MASH. The refreshed materials highlight denifanstat’s progress in MASH, where a Phase 2b trial previously met histology primary and multiple secondary endpoints and the program has FDA Breakthrough Therapy designation with Phase 3 readiness, as well as the completion of a Phase 1 hepatic impairment study and the new Phase 1 combination PK data that pave the way for a planned Phase 2 trial in MASH cirrhosis (F4) in the second half of 2026. The company also underscores growing momentum in dermatology, with licensee Ascletis having reported that a Phase 3 acne trial of denifanstat in China met all primary and secondary endpoints and that a new drug application for moderate to severe acne was accepted by China’s NMPA in December 2025, while Sagimet advances TVB-3567 in a first-in-human Phase 1 acne study, collectively strengthening its clinical pipeline and reinforcing its strategic positioning in metabolic and inflammatory diseases. The most recent analyst rating on (SGMT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page. Spark’s Take on SGMT Stock According to Spark, TipRanks’ AI Analyst, SGMT is a Neutral. Sagimet Biosciences’ overall score reflects substantial financial difficulties marked by persistent losses and reliance on external funding. While technical indicators show short-term bullish momentum, the lack of profitability and negative equity pose significant long-term risks. Valuation metrics further highlight the challenges in viewing this stock as an attractive investment. To see Spark’s full report on SGMT stock, click here. More about Sagimet Biosciences, Inc. Class A Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors targeting metabolic dysfunction-driven diseases including metabolic dysfunction-associated steatohepatitis (MASH), acne and certain cancers. Its lead oral, once-daily FASN inhibitor denifanstat has shown proof-of-concept across multiple indications, including successful Phase 2b results in MASH and positive Phase 3 acne data in China via partner Ascletis, while follow-on FASN inhibitor TVB-3567 is in early-stage development for acne. The Nasdaq-listed company (ticker: SGMT) reported $125.5 million in cash, cash equivalents and marketable securities as of 30 September 2025, which it expects to fund operations for about two years, and holds a broad intellectual property portfolio covering denifanstat, TVB-3567 and their potential combinations, including with thyroid hormone receptor beta agonist resmetirom. Average Trading Volume: 574,310 Technical Sentiment Signal: Hold Current Market Cap: $187.6M For a thorough assessment of SGMT stock, go to TipRanks’ Stock Analysis page.